AR076305A1 - Composiciones de capsulas biodisponibles de compuesto alfa-(n-sulfonamido) acetamida amorfo - Google Patents

Composiciones de capsulas biodisponibles de compuesto alfa-(n-sulfonamido) acetamida amorfo

Info

Publication number
AR076305A1
AR076305A1 ARP100101257A ARP100101257A AR076305A1 AR 076305 A1 AR076305 A1 AR 076305A1 AR P100101257 A ARP100101257 A AR P100101257A AR P100101257 A ARP100101257 A AR P100101257A AR 076305 A1 AR076305 A1 AR 076305A1
Authority
AR
Argentina
Prior art keywords
peg
pvp
capsule
polyethylene glycol
pharmaceutical
Prior art date
Application number
ARP100101257A
Other languages
English (en)
Inventor
Christopher P Price
Robert Kevin Perrone
Kalani Levons Jaquan
Sachin Chandran
Rajesh Babulal Gandhi
Jaquan Kalani Levons
Krishnaswamy Srinivas Raghavan
Ismat Ullah
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR076305A1 publication Critical patent/AR076305A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmacéuticas en cápsulas que contienen el compuesto activo (2R)-2-[[(4-clorofenil)sulfonil][[2-fluoro-4-(1,2,4-oxadiazol-3-iI)fenil]metil]amino]-5,5,5-trifluoropentanamida, y polietilenglicol (PEG), Vitamina E succinato de polietilenglicol, polivinilpirrolidona (PVP) o copovidona (PVP-acetato de polivinilo), con o sin ácido cítrico. Reivindicacion 1: Una composicion caracterizada porque comprende aproximadamente de 0,1 a 20% de (2R)2-[[(4-clorofenil)sulfonil][[2-fluoro-4-(1,2,4-oxadiazol-3-iI)fenil]metil]amino]-5,5,5-trifluoropentanamida, hasta aproximadamente 90% de polietilenglicol (PEG) y hasta aproximadamente 90% de Vitamina E succinato de polietilenglicol (TPGS), aproximadamente de 0,1 a 20% de un miembro inhibidor de la cristalizacion seleccionado del grupo constituido por polivinilpirrolidona (PVP) y copovidona (PVP-acetato de polivinilo); y aproximadamente de 0,05 a 5% de ácido cítrico. Reivindicacion 6: La composicion farmacéutica de la reivindicacion 3, caracterizada porque dicho PEG es PEG 1450. Reivindicacion 11: La cápsula farmacéutica de la reivindicacion 10, caracterizada porque dicha cápsula es una cápsula de gelatina dura. Reivindicacion 19: La composicion farmacéutica de la reivindicacion 15, caracterizada porque dicho PEG es PEG 400. Reivindicacion 23: La cápsula farmacéutica de la reivindicacion 22, caracterizada porque dicha capsula es una cápsula de gelatina blanda. Reivindicacion 28: Un procedimiento de fabricacion de una composicion farmacéutica, caracterizado porque comprende disolver (2R)-2-[[(4-clorofenil)sulfonil][[2-fluoro-4-(1,2,4-oxadiazol-3-iI)fenil]metil]amino]-5,5,5-trifluoropentanamida en una mezcla de PEG, TPGS y un miembro inhibidor de la cristalizacion seleccionado del grupo constituido por PVP y copovidona.
ARP100101257A 2009-04-14 2010-04-14 Composiciones de capsulas biodisponibles de compuesto alfa-(n-sulfonamido) acetamida amorfo AR076305A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16906109P 2009-04-14 2009-04-14

Publications (1)

Publication Number Publication Date
AR076305A1 true AR076305A1 (es) 2011-06-01

Family

ID=42235859

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101257A AR076305A1 (es) 2009-04-14 2010-04-14 Composiciones de capsulas biodisponibles de compuesto alfa-(n-sulfonamido) acetamida amorfo

Country Status (14)

Country Link
US (1) US8252821B2 (es)
EP (1) EP2419090B1 (es)
JP (1) JP2012524092A (es)
KR (1) KR20120022766A (es)
CN (1) CN102395361A (es)
AR (1) AR076305A1 (es)
AU (1) AU2010236602A1 (es)
BR (1) BRPI1015483A2 (es)
CA (1) CA2758847A1 (es)
EA (1) EA201101286A1 (es)
MX (1) MX2011010514A (es)
NZ (1) NZ595335A (es)
TW (1) TW201041609A (es)
WO (1) WO2010120755A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51155B (sr) 2001-12-20 2010-10-31 Bristol-Myers Squibb Company DERIVATI α -(N-SULFONAMIDO)ACETAMIDA KAO INHIBITORI β -AMILOIDA
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
JP2013507033A (ja) 2009-10-02 2013-02-28 エルジー エレクトロニクス インコーポレイティド ダウンリンク参照信号の転送方法及び装置
RU2618456C2 (ru) * 2010-12-16 2017-05-03 Плэтформ Брайтворкс Ту, Лтд Фармацевтические препараты азолов для парентерального введения и способы их получения и применения для лечения заболеваний, чувствительных к азольным соединениям
EP3238709B1 (en) 2011-04-28 2020-07-01 Platform Brightworks Two, Ltd. Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
SG11202109102PA (en) * 2019-02-22 2021-09-29 Janssen Pharmaceutica Nv Pharmaceutical formulations
CN115884773A (zh) * 2020-08-21 2023-03-31 詹森药业有限公司 药物制剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
BR9611487A (pt) * 1995-11-17 1999-01-19 Warner Lambert Co Inibidores de sulfonamida de metaloproteinases de matriz
CA2260860A1 (en) 1996-07-22 1998-01-29 Monsanto Company Thiol sulfonamide metalloprotease inhibitors
CA2264718C (en) * 1996-09-01 2006-05-30 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
WO2000044716A1 (en) 1999-01-27 2000-08-03 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
NZ514453A (en) 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
AU2002333098B2 (en) * 2001-10-19 2006-03-16 Isotechnika Pharma Inc. Novel cyclosporin analog microemulsion preconcentrates
RS51155B (sr) 2001-12-20 2010-10-31 Bristol-Myers Squibb Company DERIVATI α -(N-SULFONAMIDO)ACETAMIDA KAO INHIBITORI β -AMILOIDA
KR20060002908A (ko) * 2003-03-31 2006-01-09 와이어쓰 베타 아밀로이드 생산 억제제인 플루오로- 및트리플루오로알킬-함유 헤테로사이클릭 설폰아미드 및 이의유도체
AU2004285022A1 (en) 2003-10-29 2005-05-12 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
US7163942B2 (en) 2004-04-01 2007-01-16 Pfizer Inc. Sulfonamide compounds for the treatment of neurodegenerative disorders
CA2595116A1 (en) * 2004-04-28 2005-11-10 Procarrier, Inc. Oral formulation for delivery of poorly absorbed drugs
MX2007000468A (es) 2004-07-13 2007-03-08 Hoffmann La Roche Derivados de sulfonamida.
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
KR20070088770A (ko) * 2004-12-14 2007-08-29 와이어쓰 신경변성 장애의 치료 및 예방을 위한 5-ｈｔ6 작용제의용도
CA2641013A1 (en) * 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
CA2637615A1 (en) * 2006-02-17 2007-08-30 Wyeth Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
WO2007103683A2 (en) * 2006-03-01 2007-09-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production
US8633179B2 (en) 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US20110059940A1 (en) 2008-05-08 2011-03-10 Bristol- Myers Squibb Company 2-Aryl Glycinamide Derivatives
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
JP2012520875A (ja) 2009-03-19 2012-09-10 ブリストル−マイヤーズ スクイブ カンパニー ベータアミロイドペプチド産生阻害剤としての新規アルファ−（ｎ−スルホンアミド）アセトアミド化合物
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US20110071199A1 (en) 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
TW201043269A (en) 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Also Published As

Publication number Publication date
AU2010236602A1 (en) 2011-10-13
WO2010120755A1 (en) 2010-10-21
EP2419090B1 (en) 2013-02-13
CN102395361A (zh) 2012-03-28
EP2419090A1 (en) 2012-02-22
MX2011010514A (es) 2011-11-29
NZ595335A (en) 2013-03-28
CA2758847A1 (en) 2010-10-21
KR20120022766A (ko) 2012-03-12
BRPI1015483A2 (pt) 2016-04-26
JP2012524092A (ja) 2012-10-11
EA201101286A1 (ru) 2012-04-30
US20100260837A1 (en) 2010-10-14
US8252821B2 (en) 2012-08-28
TW201041609A (en) 2010-12-01

Similar Documents

Publication Publication Date Title
AR076305A1 (es) Composiciones de capsulas biodisponibles de compuesto alfa-(n-sulfonamido) acetamida amorfo
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
ES2608818T3 (es) Métodos y formulaciones para convertir fármacos intravenosos e inyectables en formas de dosificación orales
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
AR072842A1 (es) Composicion farmaceutica estabilizada que comprende un ingrediente farmaceuticamente activo no peptidico
DOP2010000214A (es) Formulacion de capsula
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
AR054238A1 (es) Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona
CL2009000598A1 (es) Composicion farmaceutica oral que comprende particulas de liberacion pulsatil controlada en el tiempo (tpr), que contienen un farmaco poco soluble debilmente basico y un acido organico separados por una capa de liberacion sostenida, y particulas de liberacion rapida (rr); capsula que la comprende; y su uso para tratar emesis.
AR032524A1 (es) Composicion farmaceutica para capsulas moldeadas; composicion farmaceutica para envueltas de capsulas moldeadas; envuelta, elemento de union o separador de capsula moldeados por inyeccion con las mismas; forma de dosificacion farmaceutica de varios componentes y conjunto de formas de dosificacion de
EA201490014A1 (ru) Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
NZ581589A (en) Solubilized sterile injectable formulation of docetaxel without Tween 80
PE20091949A1 (es) Formulacion farmaceutica solida con liberacion retardada
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
AR051654A1 (es) Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
RS53201B (en) BENDAMUSTIN ORAL DOSAGE FORMS
EA201100430A1 (ru) Стабильная комбинированная фармацевтическая композиция
WO2005107709A3 (en) Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
AR067450A1 (es) Composicion faramaceutica que comprende la combinacion de una triazolobenzodiazepina y un agente inhibidor selectivo de la recaptura de serotonina
AR075988A1 (es) Compuesto de piridiloxi - pirrolidina inhibidor de recaptacion de serotonina y norepinefrina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de dolor cronico
CO7170181A2 (es) Nueva composición de alfentanilo para el tratamiento del dolor agudo
CO2023002650A2 (es) Formas farmacéuticas sólidas de palbociclib
ES2531241T3 (es) Composición farmacéutica líquida estable a base de trazodona

Legal Events

Date Code Title Description
FA Abandonment or withdrawal